Overview of the Sale#
Perrigo Company plc has successfully completed the sale of its branded dermacosmetics business to Karo Healthcare for a total of up to €332.6 million. This amount includes €305.6 million in immediate cash, adjusted for €5.6 million in net working capital, plus an additional €27 million contingent on meeting specific sales targets over the next three years. The brands involved in this sale include ACO, Biodermal, Emolium, and Iwostin.
Financial Implications#
The proceeds from this sale will primarily be used to reduce Perrigo's debt, which currently stands at $3.85 billion. The company has a debt-to-equity ratio of 1.31, indicating a significant amount of debt relative to its equity. In 2025, the sold dermacosmetics business generated around €120 million in net sales, contributing about 5% to Perrigo's adjusted operating income.
Strategic Focus#
Patrick Lockwood-Taylor, Perrigo's CEO, stated that this transaction is part of the company's plan to stabilize, streamline, and strengthen its operations. By focusing on core categories and simplifying its portfolio, Perrigo aims to enhance its competitive advantages and achieve more consistent growth in shareholder value. Analysts suggest that the stock may be undervalued, with expectations of a return to profitability this year despite recent challenges.
Recent Financial Performance#
In its latest earnings report for the fourth quarter of 2025, Perrigo reported an earnings per share (EPS) of $0.77, slightly below the expected $0.79. However, the company surpassed revenue forecasts by $10 million, indicating resilience in a challenging market. Additionally, Perrigo announced a shift in its financial reporting structure from a geographic focus to one based on product categories, effective in the first quarter of 2026. This change aims to better align financial disclosures with its product offerings.